Study Summary
The goal of this study is to treat patients diagnosed with relapsed or refractory positive B cell lymphoma - positive for 2 or more target antigens - with CAR19.20.22 CAR T-cells. Based on the preclinical characteristics of the LTG2950, CAR19.20.22 tri-specific CAR T-cells the Investigators have developed the following hypotheses to be tested in our phase Ia clinical trial. The Investigators hypothesize that these novel CAR T-cells will show: * good safety and tolerability * a high degree of efficacy * very good persistence * an acceptable level of exhaustion
Want to learn more about this trial?
Request More InfoInterventions
CD19.20.22 CAR T cellsBIOLOGICAL
CAR19.20.22 is a type of immunotherapy known as a chimeric antigen receptor T-cells (CAR T-cells).
Fludarabine and CyclophosphamideDRUG
Lymphodepletion with Flu-Cy prior to CAR T cell therapy
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| University of Maryland, Baltimore | Baltimore | Maryland | United States |